ArticleNature communications2021
Characterization of a new Leishmania major strain for use in a controlled human infection model.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 50 citations in OpenAlex.
- Harnessing controlled human infection models to accelerate vaccine development for neglected tropical diseases: Lessons from leishmaniasis.European journal of clinical investigation · 2026Review
- In Vitro and in Vivo Therapeutic Evaluation of Ethanolic Extract of Sumac and Compounds of Linalool and Eugenol Against Localized Cutaneous Leishmaniasis Induced by Leishmania major.Acta parasitologica · 2025Article
- Infectiousness of Leishmania major to Phlebotomus papatasi: differences between natural reservoir host Meriones shawi and laboratory model BALB/c mice.PLoS neglected tropical diseases · 2025Article
- Detection of Leishmania metacyclogenesis within the sand fly vector employing a real-time PCR for sherp gene expression: A tool for Leishmania surveillance and transmission potential.PLoS neglected tropical diseases · 2025Article
- Targeting Leishmaniasis with Nitrovinyl Derivatives: Synthesis,Current medicinal chemistry · 2025Article
- Safety and reactogenicity of a controlled human infection model of sand fly-transmitted cutaneous leishmaniasis.Nature medicine · 2024Observational
- The development of L. major, L. donovani and L. martiniquensis, Leishmania currently emerging in Europe, in the sand fly species Phlebotomus perniciosus and P. tobbi.PLoS neglected tropical diseases · 2024Article
- Ex Vivo Analysis of the Association of GFP-ExpressingMicroorganisms · 2024Article
- Preparation and characterization of artemether-loaded niosomes in Leishmania major-induced cutaneous leishmaniasis.Scientific reports · 2024Article
- Synthetic biology for combating leishmaniasis.Frontiers in microbiology · 2024Article
- Shared challenges to the control of complex intracellular neglected pathogens.Frontiers in public health · 2024Review
- Production of leishmanin skin test antigen from Leishmania donovani for future reintroduction in the field.Nature communications · 2023Article
- From Infection to Death: An Overview of the Pathogenesis of Visceral Leishmaniasis.Pathogens (Basel, Switzerland) · 2023Review
- Pharmacological Features of 18β-Glycyrrhetinic Acid: A Pentacyclic Triterpenoid of Therapeutic Potential.Plants (Basel, Switzerland) · 2023Review
- Niosome as an Effective Nanoscale Solution for the Treatment of Microbial Infections.BioMed research international · 2023Review
- Human infection challenge in the pandemic era and beyond, HIC-Vac annual meeting report, 2022.Immunotherapy advances · 2023Review
- Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs.Pathogens (Basel, Switzerland) · 2022Review
- Bioinformatics analysis for the purpose of designing a novel multi-epitope DNA vaccine against Leishmania major.Scientific reports · 2022Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 4 countries.
Funding
Abstract
Leishmaniasis is widely regarded as a vaccine-preventable disease, but the costs required to reach pivotal Phase 3 studies and uncertainty about which candidate vaccines should be progressed into human studies significantly limits progress in vaccine development for this neglected tropical disease. Controlled human infection models (CHIMs) provide a pathway for accelerating vaccine development and to more fully understand disease pathogenesis and correlates of protection. Here, we describe the isolation, characterization and GMP manufacture of a new clinical strain of Leishmania major. Two fresh strains of L. major from Israel were initially compared by genome sequencing, in vivo infectivity and drug sensitivity in mice, and development and transmission competence in sand flies, allowing one to be selected for GMP production. This study addresses a major roadblock in the development of vaccines for leishmaniasis, providing a key resource for CHIM studies of sand fly transmitted cutaneous leishmaniasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.